Hang Lung Group（HLU）株式概要ハンルングループ・リミテッドは投資持株会社で、香港と中国本土で不動産デベロッパーとして事業を展開している。 詳細HLU ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績1/6財務の健全性3/6配当金6/6報酬当社が推定した公正価値より75.2%で取引されている 6.23%の高配当で安定した配当金を支払う リスク分析財務結果に影響を与える大きな一時的項目 すべてのリスクチェックを見るHLU Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,107 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,107 investors already sharing narrativesYour Fair Value€Current Price€1.4751.5% 割高 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2b14b2016201920222025202620282031Revenue HK$11.5bEarnings HK$1.5bAdvancedSet Fair ValueView all narrativesHang Lung Group Limited 競合他社AroundtownSymbol: XTRA:AT1Market cap: €2.1bGrand City PropertiesSymbol: XTRA:GYCMarket cap: €1.7bTAG ImmobilienSymbol: XTRA:TEGMarket cap: €2.4bDeutsche EuroShopSymbol: XTRA:DEQMarket cap: €1.4b価格と性能株価の高値、安値、推移の概要Hang Lung Group過去の株価現在の株価HK$1.4752週高値HK$1.8752週安値HK$1.35ベータ0.661ヶ月の変化4.26%3ヶ月変化-15.03%1年変化0%3年間の変化4.26%5年間の変化-27.94%IPOからの変化72.94%最新ニュースお知らせ • Jul 03Hang Lung Group Limited to Report First Half, 2026 Results on Jul 31, 2026Hang Lung Group Limited announced that they will report first half, 2026 results on Jul 31, 2026Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Non-Executive Director May Tan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 30+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2026Hang Lung Group Limited, Annual General Meeting, Apr 30, 2026.お知らせ • Jan 02Hang Lung Group Limited to Report Fiscal Year 2025 Results on Jan 30, 2026Hang Lung Group Limited announced that they will report fiscal year 2025 results on Jan 30, 2026お知らせ • Jul 03Hang Lung Group Limited to Report First Half, 2025 Results on Jul 30, 2025Hang Lung Group Limited announced that they will report first half, 2025 results on Jul 30, 2025お知らせ • Jan 24+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2025Hang Lung Group Limited, Annual General Meeting, Apr 30, 2025.最新情報をもっと見るRecent updatesお知らせ • Jul 03Hang Lung Group Limited to Report First Half, 2026 Results on Jul 31, 2026Hang Lung Group Limited announced that they will report first half, 2026 results on Jul 31, 2026Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Non-Executive Director May Tan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Jan 30+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2026Hang Lung Group Limited, Annual General Meeting, Apr 30, 2026.お知らせ • Jan 02Hang Lung Group Limited to Report Fiscal Year 2025 Results on Jan 30, 2026Hang Lung Group Limited announced that they will report fiscal year 2025 results on Jan 30, 2026お知らせ • Jul 03Hang Lung Group Limited to Report First Half, 2025 Results on Jul 30, 2025Hang Lung Group Limited announced that they will report first half, 2025 results on Jul 30, 2025お知らせ • Jan 24+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2025Hang Lung Group Limited, Annual General Meeting, Apr 30, 2025.お知らせ • Jan 03Hang Lung Group Limited to Report Fiscal Year 2024 Results on Jan 24, 2025Hang Lung Group Limited announced that they will report fiscal year 2024 results at 12:30 PM, China Standard Time on Jan 24, 2025Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.19, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 13x in the Real Estate industry in Germany. Total loss to shareholders of 26% over the past three years.Reported Earnings • Sep 18First half 2024 earnings released: EPS: HK$0.65 (vs HK$1.24 in 1H 2023)First half 2024 results: EPS: HK$0.65 (down from HK$1.24 in 1H 2023). Revenue: HK$6.51b (up 16% from 1H 2023). Net income: HK$888.0m (down 47% from 1H 2023). Profit margin: 14% (down from 30% in 1H 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.Upcoming Dividend • Aug 07Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 14 August 2024. Payment date: 25 September 2024. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 10%. Within top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.9%).Reported Earnings • Aug 01First half 2024 earnings released: EPS: HK$0.65 (vs HK$1.24 in 1H 2023)First half 2024 results: EPS: HK$0.65 (down from HK$1.24 in 1H 2023). Revenue: HK$6.51b (up 16% from 1H 2023). Net income: HK$888.0m (down 47% from 1H 2023). Profit margin: 14% (down from 30% in 1H 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.New Risk • Jul 31New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 17% Last year net profit margin: 27% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (17% net profit margin).New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).お知らせ • Jul 04Hang Lung Group Limited to Report First Half, 2024 Results on Jul 30, 2024Hang Lung Group Limited announced that they will report first half, 2024 results on Jul 30, 2024お知らせ • Jun 21Hang Lung Group Limited Announces Audit Committee Changes, Effective July 1, 2024The board of Hang Lung Group Limited announced changes to the composition of the Audit Committee of the Company with effect from July 1, 2024. Professor Lap-Chee TSUI, an independent non-executive director of the Company, will cease to be a member of the Audit Committee; and Ms. May Siew Boi TAN, an independent non-executive director of the Company, will be appointed as a member of the Audit Committee. Professor TSUI will remain as an independent non-executive director of the Company.Reported Earnings • Mar 31Full year 2023 earnings released: EPS: HK$2.06 (vs HK$2.00 in FY 2022)Full year 2023 results: EPS: HK$2.06 (up from HK$2.00 in FY 2022). Revenue: HK$11.0b (flat on FY 2022). Net income: HK$2.81b (up 3.4% from FY 2022). Profit margin: 26% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.Recent Insider Transactions • Feb 09Executive Vice Chair of the Board recently bought €230k worth of stockOn the 2nd of February, Wenbwo Chan bought around 200k shares on-market at roughly €1.15 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Wenbwo has been a buyer over the last 12 months, purchasing a net total of €569k worth in shares.Declared Dividend • Feb 01Final dividend of HK$0.65 announcedShareholders will receive a dividend of HK$0.65. Ex-date: 8th May 2024 Payment date: 14th June 2024 Dividend yield will be 62%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has increased over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to decline by 54% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.お知らせ • Jan 31Hang Lung Properties Limited and Hang Lung Group Limited Announce Retirement of Mr. Ronnie Chichung Chan as the Chair, an Executive Director, and the Chair of Executive Committees, with Effect from April 26, 2024The Boards of Directors of Hang Lung Group Limited (HLG) and Hang Lung Properties Limited (HLP, together with HLG, referred to as the Group) jointly announced that Mr. Ronnie Chichung CHAN (Mr. Ronnie Chan) will retire from his positions as the Chair, an Executive Director, and the Chair of Executive Committees of the Group with effect from the conclusion of the annual general meeting of each of HLG and HLP to be held on April 26, 2024 (the "2024 AGM"). Mr. Ronnie Chan will not take up a Non-Executive Director role in the Boards after his retirement. Mr. Ronnie Chan joined the Group in 1972 and has led the Group as the Chair since 1991. Mr. Ronnie Chan's vision and leadership established a strong foundation for the Group's sustainable growth. The Boards would like to express their deep gratitude to Mr. Ronnie Chan for his tremendous contributions to the Group. In recognition of his tremendous contributions, the Boards will bestow upon Mr. Ronnie Chan the title of the "Honorary Chair" of the Group after his retirement.Reported Earnings • Jan 31Full year 2023 earnings released: EPS: HK$2.06 (vs HK$2.00 in FY 2022)Full year 2023 results: EPS: HK$2.06 (up from HK$2.00 in FY 2022). Revenue: HK$11.0b (flat on FY 2022). Net income: HK$2.81b (up 3.4% from FY 2022). Profit margin: 26% (up from 25% in FY 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.お知らせ • Jan 30+ 1 more updateHang Lung Group Limited Appoints Ms. May Siew Boi Tan as an Independent Non-Executive Director, with Effect from March 20, 2024The Board of Directors of Hang Lung Group Limited announced that Ms. May Siew Boi TAN ("Ms. Tan") will be appointed as an Independent Non-Executive Director ("INED") of the Company with effect from March 20, 2024. Ms. Tan, aged 68, graduated from The University of Sheffield, and is a Fellow of The Institute of Chartered Accountants in England and Wales and a Fellow of The Hong Kong Institute of Certified Public Accountants. Ms. Tan is an INED, the Chair of the Audit & Risk Committee, and a Member of the Nomination Committee, the Finance & General Committee, the Sustainability Committee, and the Human Resources & Remuneration Committee, of CLP Holdings Limited. She is also an INED, a Member of the Audit Committee and the Corporate Governance and Nominating Committee, of Manulife Financial Corporation. She holds the positions as a Board Member of Anticimex New TopHolding AB; and a Director of MSIG Insurance (Hong Kong) Limited. Ms. Tan was an INED of JPMorgan China Growth & Income plc from August 2021 to January 2024; an INED of Link Asset Management Ltd. (as manager of Link Real Estate Investment Trust) from February 2013 to January 2022; and an INED of HSBC Insurance (Asia) Limited and HSBC Life (International) Limited from 2018 to 2021. She was an Executive Director and the Chief Executive Officer of Standard Chartered Bank (Hong Kong) Limited* from July 2014 to February 2017. Ms. Tan joined Standard Chartered Bank in 2009 as Global Head, Equity Corporate Finance. She was previously the Chief Executive Officer of Cazenove Asia Limited, and was a partner of Cazenove and Co. Cazenove Asia Limited (now known as Standard Chartered Securities (Hong Kong) Limited) became part of Standard Chartered Hong Kong in January 2009. Service from 2015 to 2020. In 2016, Ms. Tan was the Chairman of the Hong Kong Association of Banks, the Ex-officio Member of The Hong Kong Trade Development Council and a Member of the Currency Board Sub-Committee of the Exchange Fund Advisory Committee of Hong Kong Monetary Authority. She was a Member of the Listing Committee of The Stock Exchange of Hong Kong Limited from 2012 to 2015 and a Member of the Takeovers and Mergers Panel and the Takeovers Appeal Committee of the Securities and Futures Commission from 2001 to 2013. Ms. Tan was also a Council Member from 2008 to 2017 and the Vice Chairman from 2012 to 2017 of Oxfam Hong Kong.お知らせ • Jan 06Hang Lung Group Limited to Report Fiscal Year 2023 Results on Jan 30, 2024Hang Lung Group Limited announced that they will report fiscal year 2023 results on Jan 30, 2024Upcoming Dividend • Sep 05Upcoming dividend of HK$0.21 per share at 7.8% yieldEligible shareholders must have bought the stock before 12 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 7.8%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (3.6%).Reported Earnings • Aug 02First half 2023 earnings released: EPS: HK$1.24 (vs HK$1.06 in 1H 2022)First half 2023 results: EPS: HK$1.24 (up from HK$1.06 in 1H 2022). Revenue: HK$5.60b (down 2.2% from 1H 2022). Net income: HK$1.68b (up 17% from 1H 2022). Profit margin: 30% (up from 25% in 1H 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.お知らせ • Aug 01Hang Lung Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 29 September 2023Hang Lung Group Limited announced Interim Dividend for the six months ended 30 June 2023 of HKD 0.21 per share. Ex-dividend date 12 September 2023. Record date 15 September 2023. Payment date 29 September 2023.お知らせ • Jul 04Hang Lung Group Limited to Report First Half, 2023 Results on Jul 31, 2023Hang Lung Group Limited announced that they will report first half, 2023 results on Jul 31, 2023Upcoming Dividend • Apr 26Upcoming dividend of HK$0.65 per share at 6.3% yieldEligible shareholders must have bought the stock before 03 May 2023. Payment date: 19 May 2023. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (3.9%).Reported Earnings • Apr 06Full year 2022 earnings released: EPS: HK$2.00 (vs HK$1.90 in FY 2021)Full year 2022 results: EPS: HK$2.00 (up from HK$1.90 in FY 2021). Revenue: HK$11.1b (up 1.7% from FY 2021). Net income: HK$2.72b (up 5.0% from FY 2021). Profit margin: 25% (in line with FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.Buying Opportunity • Feb 16Now 20% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €2.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.7% over the last 3 years. Earnings per share has declined by 9.6%.Reported Earnings • Feb 02Full year 2022 earnings released: EPS: HK$2.00 (vs HK$1.90 in FY 2021)Full year 2022 results: EPS: HK$2.00 (up from HK$1.90 in FY 2021). Revenue: HK$10.9b (flat on FY 2021). Net income: HK$2.72b (up 5.0% from FY 2021). Profit margin: 25% (up from 24% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year and the company’s share price has also fallen by 10% per year.お知らせ • Feb 01Hang Lung Group Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 19 May 2023Hang Lung Group Limited proposed Final Dividend of HKD 0.65 per share for the year ended 31 December 2022. Ex-dividend date is 03 May 2023. Record date is 05 May 2023. Payment date is 19 May 2023. Date of shareholders' approval is 28 April 2023.Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Pak Wai Liu was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Reported Earnings • Sep 18First half 2022 earnings released: EPS: HK$1.06 (vs HK$1.11 in 1H 2021)First half 2022 results: EPS: HK$1.06 (down from HK$1.11 in 1H 2021). Revenue: HK$5.72b (up 9.1% from 1H 2021). Net income: HK$1.44b (down 4.6% from 1H 2021). Profit margin: 25% (down from 29% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Sep 02Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 09 September 2022. Payment date: 29 September 2022. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 6.4%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (5.2%).Recent Insider Transactions • Aug 16CEO & Executive Director recently bought €83k worth of stockOn the 10th of August, Wai Pak Lo bought around 50k shares on-market at roughly €1.67 per share. This was the largest purchase by an insider in the last 3 months. Wai Pak has been a buyer over the last 12 months, purchasing a net total of €492k worth in shares.Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down HK$1.51b from profit in 1H 2021). Profit margin: (down from 29% in 1H 2021). The decrease in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Jul 29Hang Lung Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2022, Payable on 29 September 2022Hang Lung Group Limited announced Interim Dividend for the six months ended 30 June 2022. Dividend declared is HKD 0.21 per share. Ex-dividend date is 09 September 2022. Record date is 15 September 2022. Payment date is 29 September 2022.お知らせ • Jul 05Hang Lung Group Limited to Report First Half, 2022 Results on Jul 28, 2022Hang Lung Group Limited announced that they will report first half, 2022 results on Jul 28, 2022お知らせ • Apr 28Hang Lung Group Limited Approves Final DividendHang Lung Group Limited approved the final dividend of 65 Hong Kong cents per share in annual general meeting held on April 27, 2022.Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Pak Wai Liu was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 22Upcoming dividend of HK$0.65 per shareEligible shareholders must have bought the stock before 29 April 2022. Payment date: 19 May 2022. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 5.2%. Within top quartile of German dividend payers (3.8%). Higher than average of industry peers (3.7%).Reported Earnings • Jan 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: HK$1.90 (up from HK$1.13 loss in FY 2020). Revenue: HK$10.9b (up 18% from FY 2020). Net income: HK$2.59b (up HK$4.13b from FY 2020). Profit margin: 24% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Revenue missed analyst estimates by 11%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.お知らせ • Jan 28+ 1 more updateHang Lung Group Limited Proposes Final Dividend for the Year Ended December 31, 2021, Payable on May 19, 2022Hang Lung Group Limited proposed final dividend of HKD 0.65 per share for the year ended December 31, 2021. Ex-dividend date is April 29, 2022. Record date is May 04, 2022. Payment date is May 19, 2022.Reported Earnings • Sep 18First half 2021 earnings released: EPS HK$1.11 (vs HK$1.17 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$5.24b (up 22% from 1H 2020). Net income: HK$1.51b (up HK$3.10b from 1H 2020). Profit margin: 29% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Recent Insider Transactions • Sep 12CEO & Executive Director recently bought €307k worth of stockOn the 8th of September, Wai Pak Lo bought around 150k shares on-market at roughly €2.05 per share. This was the largest purchase by an insider in the last 3 months. This was Wai Pak's only on-market trade for the last 12 months.Upcoming Dividend • Sep 03Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 10 September 2021. Payment date: 29 September 2021. Trailing yield: 4.4%. Within top quartile of German dividend payers (3.1%). Higher than average of industry peers (2.9%).Recent Insider Transactions • Sep 02CFO & Executive Director recently bought €61k worth of stockOn the 26th of August, Hau Cheong Ho bought around 29k shares on-market at roughly €2.11 per share. This was the largest purchase by an insider in the last 3 months. Hau Cheong has been a buyer over the last 12 months, purchasing a net total of €107k worth in shares.Reported Earnings • Aug 02First half 2021 earnings released: EPS HK$1.11 (vs HK$1.17 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$5.24b (up 22% from 1H 2020). Net income: HK$1.51b (up HK$3.10b from 1H 2020). Profit margin: 29% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Executive Departure • May 07Director of General Counsel has left the companyOn the 1st of May, Ka Man Yan's tenure as Director of General Counsel ended after 3.8 years in the role. We don't have any record of a personal shareholding under Ka Man's name. Ka Man is the only executive to leave the company over the last 12 months.お知らせ • May 01Hang Lung Group Limited Declares Final Dividend for the Year 2020Hang Lung Group Limited declares a final dividend of 63 Hong Kong cents per share, at its AGM to be held on April 29, 2020.Upcoming Dividend • Apr 27Upcoming dividend of HK$0.63 per shareEligible shareholders must have bought the stock before 04 May 2021. Payment date: 20 May 2021. Trailing yield: 4.0%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.1%).Reported Earnings • Mar 26Full year 2020 earnings released: HK$1.13 loss per share (vs HK$5.01 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: HK$9.24b (down 4.0% from FY 2019). Net loss: HK$1.54b (down 123% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.Reported Earnings • Jan 29Full year 2020 earnings released: HK$1.13 loss per share (vs HK$5.01 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: HK$9.53b (down 1.0% from FY 2019). Net loss: HK$1.54b (down 123% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.お知らせ • Jan 28Hang Lung Group Limited, Annual General Meeting, Apr 30, 2021Hang Lung Group Limited, Annual General Meeting, Apr 30, 2021.Is New 90 Day High Low • Jan 27New 90-day high: €2.26The company is up 19% from its price of €1.90 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Real Estate industry, which is up 9.0% over the same period.お知らせ • Jan 07Hang Lung Group Limited to Report Fiscal Year 2020 Results on Jan 28, 2021Hang Lung Group Limited announced that they will report fiscal year 2020 results on Jan 28, 2021お知らせ • Nov 21Hang Lung Group Limited Enters into the Lease Agreement as Tenant with Hang Lung as the LandlordThe Board announced that Top Glorification, an indirect wholly-owned subsidiary of the Company, entered into the Lease Agreement as tenant with Hang Lung as the landlord in respect of the Premises on 20 November 2020, for a term of three years commencing on 1 November 2020 and expiring on 31 October 2023 (both days inclusive) for the operation of its restaurant "Duddell's". Pursuant to HKFRS 16, the entering into of the Agreement will require the Group to recognise the fixed portion of the lease payment for the Premises as the right-of-use assets with a cost of approximately HKD 19.0 million at initial recognition and a corresponding lease liability which represented the present value of the future lease payments. Thus, the entering into the Lease Agreement and the transactions contemplated thereunder will be regarded as deemed acquisition of asset by the Group. REASONS FOR AND BENEFITS OF ENTERING INTO THE LEASE AGREEMENT: The Group is principally engaged in operating restaurants and providing membership services for the Group's restaurants in Hong Kong. The Premises have been leased to Top Glorification since May 2013 to operate the Group 's restaurant "Duddell's". The existing lease agreement for the Premises will expire on 31 October 2020. The Lease Agreement allows "Duddell's" to operate in the same location at Premises after the expiry of the existing lease agreement on 31 October 2020, which will facilitate the long-term success of the restaurant. Based on the above, the Directors are of the view that the terms and conditions of the Lease Agreement are fair and reasonable and in the interests of the Company and its shareholders as a whole.Is New 90 Day High Low • Oct 31New 90-day low: €1.88The company is down 7.0% from its price of €2.02 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Real Estate industry, which is down 2.0% over the same period.Is New 90 Day High Low • Sep 29New 90-day low: €1.94The company is down 6.0% from its price of €2.06 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Real Estate industry, which is up 4.0% over the same period.株主還元HLUDE Real EstateDE 市場7D0%-1.8%-1.0%1Y0%-20.7%-2.2%株主還元を見る業界別リターン: HLU過去 1 年間で-20.7 % の収益を上げたGerman Real Estate業界を上回りました。リターン対市場: HLUは、過去 1 年間で-2.2 % のリターンをもたらしたGermanマーケットと一致しました。価格変動Is HLU's price volatile compared to industry and market?HLU volatilityHLU Average Weekly Movement2.9%Real Estate Industry Average Movement4.9%Market Average Movement5.4%10% most volatile stocks in DE Market12.8%10% least volatile stocks in DE Market2.7%安定した株価: HLU 、 German市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: HLUの 週次ボラティリティ ( 3% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19604,595Weber Lowww.hanglung.comハンルングループ・リミテッドは投資持株会社で、香港と中国本土で不動産デベロッパーとして事業を展開している。不動産賃貸事業、不動産販売事業、ホテル事業を行っている。同社は、小売、オフィス、住宅、サービスアパートメントなどの売買・賃貸用不動産を開発している。また、ホテル、ショッピングモール、オフィス、工業施設、住宅、駐車場なども運営している。さらに、不動産管理、金融、アパートの運営・管理、マネジメント、不動産仲介、ホテル投資サービス、賃貸収入を目的とした不動産投資サービスも提供している。ハンルン・グループ・リミテッドは1960年に設立され、香港のセントラルに本社を置いている。もっと見るHang Lung Group Limited 基礎のまとめHang Lung Group の収益と売上を時価総額と比較するとどうか。HLU 基礎統計学時価総額€2.11b収益（TTM）€153.56m売上高(TTM)€1.17b13.7xPER（株価収益率1.8xP/SレシオHLU は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計HLU 損益計算書（TTM）収益HK$10.46b売上原価HK$3.58b売上総利益HK$6.88bその他の費用HK$5.51b収益HK$1.37b直近の収益報告Dec 31, 2025次回決算日Jul 31, 2026一株当たり利益（EPS）1.01グロス・マージン65.80%純利益率13.10%有利子負債／自己資本比率35.3%HLU の長期的なパフォーマンスは？過去の実績と比較を見る配当金6.2%現在の配当利回り85%配当性向View Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/07/23 03:52終値2026/07/23 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Hang Lung Group Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Andrew LawrenceBarclaysAnthony WuGoldman SachsVenant ChiangJefferies LLC2 その他のアナリストを表示
お知らせ • Jul 03Hang Lung Group Limited to Report First Half, 2026 Results on Jul 31, 2026Hang Lung Group Limited announced that they will report first half, 2026 results on Jul 31, 2026
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Non-Executive Director May Tan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 30+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2026Hang Lung Group Limited, Annual General Meeting, Apr 30, 2026.
お知らせ • Jan 02Hang Lung Group Limited to Report Fiscal Year 2025 Results on Jan 30, 2026Hang Lung Group Limited announced that they will report fiscal year 2025 results on Jan 30, 2026
お知らせ • Jul 03Hang Lung Group Limited to Report First Half, 2025 Results on Jul 30, 2025Hang Lung Group Limited announced that they will report first half, 2025 results on Jul 30, 2025
お知らせ • Jan 24+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2025Hang Lung Group Limited, Annual General Meeting, Apr 30, 2025.
お知らせ • Jul 03Hang Lung Group Limited to Report First Half, 2026 Results on Jul 31, 2026Hang Lung Group Limited announced that they will report first half, 2026 results on Jul 31, 2026
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 6 non-independent directors. Independent Non-Executive Director May Tan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Jan 30+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2026Hang Lung Group Limited, Annual General Meeting, Apr 30, 2026.
お知らせ • Jan 02Hang Lung Group Limited to Report Fiscal Year 2025 Results on Jan 30, 2026Hang Lung Group Limited announced that they will report fiscal year 2025 results on Jan 30, 2026
お知らせ • Jul 03Hang Lung Group Limited to Report First Half, 2025 Results on Jul 30, 2025Hang Lung Group Limited announced that they will report first half, 2025 results on Jul 30, 2025
お知らせ • Jan 24+ 1 more updateHang Lung Group Limited, Annual General Meeting, Apr 30, 2025Hang Lung Group Limited, Annual General Meeting, Apr 30, 2025.
お知らせ • Jan 03Hang Lung Group Limited to Report Fiscal Year 2024 Results on Jan 24, 2025Hang Lung Group Limited announced that they will report fiscal year 2024 results at 12:30 PM, China Standard Time on Jan 24, 2025
Valuation Update With 7 Day Price Move • Oct 01Investor sentiment improves as stock rises 17%After last week's 17% share price gain to €1.19, the stock trades at a trailing P/E ratio of 7.1x. Average trailing P/E is 13x in the Real Estate industry in Germany. Total loss to shareholders of 26% over the past three years.
Reported Earnings • Sep 18First half 2024 earnings released: EPS: HK$0.65 (vs HK$1.24 in 1H 2023)First half 2024 results: EPS: HK$0.65 (down from HK$1.24 in 1H 2023). Revenue: HK$6.51b (up 16% from 1H 2023). Net income: HK$888.0m (down 47% from 1H 2023). Profit margin: 14% (down from 30% in 1H 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 19% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Aug 07Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 14 August 2024. Payment date: 25 September 2024. Payout ratio is a comfortable 58% and this is well supported by cash flows. Trailing yield: 10%. Within top quartile of German dividend payers (4.9%). Higher than average of industry peers (2.9%).
Reported Earnings • Aug 01First half 2024 earnings released: EPS: HK$0.65 (vs HK$1.24 in 1H 2023)First half 2024 results: EPS: HK$0.65 (down from HK$1.24 in 1H 2023). Revenue: HK$6.51b (up 16% from 1H 2023). Net income: HK$888.0m (down 47% from 1H 2023). Profit margin: 14% (down from 30% in 1H 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 6% per year but the company’s share price has fallen by 23% per year, which means it is significantly lagging earnings.
New Risk • Jul 31New minor risk - Profit margin trendThe company's profit margins are lower than last year and have reduced by more than 30%. Net profit margin: 17% Last year net profit margin: 27% This is considered a minor risk. A large drop in profit margin could indicate the company does not have strong competitive advantages or it is yet to establish itself and its core business. Even if it is a well established business, this may make it a much riskier investment than one that has a combination of proven competitive advantages and a stable or growing profit margin. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 12% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Profit margins are more than 30% lower than last year (17% net profit margin).
New Risk • Jul 29New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 6.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 18% per year over the past 5 years. Minor Risk Share price has been volatile over the past 3 months (6.7% average weekly change).
お知らせ • Jul 04Hang Lung Group Limited to Report First Half, 2024 Results on Jul 30, 2024Hang Lung Group Limited announced that they will report first half, 2024 results on Jul 30, 2024
お知らせ • Jun 21Hang Lung Group Limited Announces Audit Committee Changes, Effective July 1, 2024The board of Hang Lung Group Limited announced changes to the composition of the Audit Committee of the Company with effect from July 1, 2024. Professor Lap-Chee TSUI, an independent non-executive director of the Company, will cease to be a member of the Audit Committee; and Ms. May Siew Boi TAN, an independent non-executive director of the Company, will be appointed as a member of the Audit Committee. Professor TSUI will remain as an independent non-executive director of the Company.
Reported Earnings • Mar 31Full year 2023 earnings released: EPS: HK$2.06 (vs HK$2.00 in FY 2022)Full year 2023 results: EPS: HK$2.06 (up from HK$2.00 in FY 2022). Revenue: HK$11.0b (flat on FY 2022). Net income: HK$2.81b (up 3.4% from FY 2022). Profit margin: 26% (in line with FY 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 21% per year, which means it is significantly lagging earnings.
Recent Insider Transactions • Feb 09Executive Vice Chair of the Board recently bought €230k worth of stockOn the 2nd of February, Wenbwo Chan bought around 200k shares on-market at roughly €1.15 per share. This transaction amounted to 67% of their direct individual holding at the time of the trade. This was the largest purchase by an insider in the last 3 months. Wenbwo has been a buyer over the last 12 months, purchasing a net total of €569k worth in shares.
Declared Dividend • Feb 01Final dividend of HK$0.65 announcedShareholders will receive a dividend of HK$0.65. Ex-date: 8th May 2024 Payment date: 14th June 2024 Dividend yield will be 62%, which is higher than the industry average of 3.1%. Sustainability & Growth Dividend is well covered by both earnings (42% earnings payout ratio) and cash flows (25% cash payout ratio). The dividend has increased over the past 10 years and has been stable with no material reductions to payments, indicating a long track record of dividend growth and stability. The company's earnings per share (EPS) would need to decline by 54% to shift the payout ratio to a potentially unsustainable range, which is more than the 12% EPS decline seen over the last 5 years.
お知らせ • Jan 31Hang Lung Properties Limited and Hang Lung Group Limited Announce Retirement of Mr. Ronnie Chichung Chan as the Chair, an Executive Director, and the Chair of Executive Committees, with Effect from April 26, 2024The Boards of Directors of Hang Lung Group Limited (HLG) and Hang Lung Properties Limited (HLP, together with HLG, referred to as the Group) jointly announced that Mr. Ronnie Chichung CHAN (Mr. Ronnie Chan) will retire from his positions as the Chair, an Executive Director, and the Chair of Executive Committees of the Group with effect from the conclusion of the annual general meeting of each of HLG and HLP to be held on April 26, 2024 (the "2024 AGM"). Mr. Ronnie Chan will not take up a Non-Executive Director role in the Boards after his retirement. Mr. Ronnie Chan joined the Group in 1972 and has led the Group as the Chair since 1991. Mr. Ronnie Chan's vision and leadership established a strong foundation for the Group's sustainable growth. The Boards would like to express their deep gratitude to Mr. Ronnie Chan for his tremendous contributions to the Group. In recognition of his tremendous contributions, the Boards will bestow upon Mr. Ronnie Chan the title of the "Honorary Chair" of the Group after his retirement.
Reported Earnings • Jan 31Full year 2023 earnings released: EPS: HK$2.06 (vs HK$2.00 in FY 2022)Full year 2023 results: EPS: HK$2.06 (up from HK$2.00 in FY 2022). Revenue: HK$11.0b (flat on FY 2022). Net income: HK$2.81b (up 3.4% from FY 2022). Profit margin: 26% (up from 25% in FY 2022). Over the last 3 years on average, earnings per share has increased by 47% per year but the company’s share price has fallen by 20% per year, which means it is significantly lagging earnings.
お知らせ • Jan 30+ 1 more updateHang Lung Group Limited Appoints Ms. May Siew Boi Tan as an Independent Non-Executive Director, with Effect from March 20, 2024The Board of Directors of Hang Lung Group Limited announced that Ms. May Siew Boi TAN ("Ms. Tan") will be appointed as an Independent Non-Executive Director ("INED") of the Company with effect from March 20, 2024. Ms. Tan, aged 68, graduated from The University of Sheffield, and is a Fellow of The Institute of Chartered Accountants in England and Wales and a Fellow of The Hong Kong Institute of Certified Public Accountants. Ms. Tan is an INED, the Chair of the Audit & Risk Committee, and a Member of the Nomination Committee, the Finance & General Committee, the Sustainability Committee, and the Human Resources & Remuneration Committee, of CLP Holdings Limited. She is also an INED, a Member of the Audit Committee and the Corporate Governance and Nominating Committee, of Manulife Financial Corporation. She holds the positions as a Board Member of Anticimex New TopHolding AB; and a Director of MSIG Insurance (Hong Kong) Limited. Ms. Tan was an INED of JPMorgan China Growth & Income plc from August 2021 to January 2024; an INED of Link Asset Management Ltd. (as manager of Link Real Estate Investment Trust) from February 2013 to January 2022; and an INED of HSBC Insurance (Asia) Limited and HSBC Life (International) Limited from 2018 to 2021. She was an Executive Director and the Chief Executive Officer of Standard Chartered Bank (Hong Kong) Limited* from July 2014 to February 2017. Ms. Tan joined Standard Chartered Bank in 2009 as Global Head, Equity Corporate Finance. She was previously the Chief Executive Officer of Cazenove Asia Limited, and was a partner of Cazenove and Co. Cazenove Asia Limited (now known as Standard Chartered Securities (Hong Kong) Limited) became part of Standard Chartered Hong Kong in January 2009. Service from 2015 to 2020. In 2016, Ms. Tan was the Chairman of the Hong Kong Association of Banks, the Ex-officio Member of The Hong Kong Trade Development Council and a Member of the Currency Board Sub-Committee of the Exchange Fund Advisory Committee of Hong Kong Monetary Authority. She was a Member of the Listing Committee of The Stock Exchange of Hong Kong Limited from 2012 to 2015 and a Member of the Takeovers and Mergers Panel and the Takeovers Appeal Committee of the Securities and Futures Commission from 2001 to 2013. Ms. Tan was also a Council Member from 2008 to 2017 and the Vice Chairman from 2012 to 2017 of Oxfam Hong Kong.
お知らせ • Jan 06Hang Lung Group Limited to Report Fiscal Year 2023 Results on Jan 30, 2024Hang Lung Group Limited announced that they will report fiscal year 2023 results on Jan 30, 2024
Upcoming Dividend • Sep 05Upcoming dividend of HK$0.21 per share at 7.8% yieldEligible shareholders must have bought the stock before 12 September 2023. Payment date: 29 September 2023. Payout ratio is a comfortable 40% and this is well supported by cash flows. Trailing yield: 7.8%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (3.6%).
Reported Earnings • Aug 02First half 2023 earnings released: EPS: HK$1.24 (vs HK$1.06 in 1H 2022)First half 2023 results: EPS: HK$1.24 (up from HK$1.06 in 1H 2022). Revenue: HK$5.60b (down 2.2% from 1H 2022). Net income: HK$1.68b (up 17% from 1H 2022). Profit margin: 30% (up from 25% in 1H 2022). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has increased by 56% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
お知らせ • Aug 01Hang Lung Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2023, Payable on 29 September 2023Hang Lung Group Limited announced Interim Dividend for the six months ended 30 June 2023 of HKD 0.21 per share. Ex-dividend date 12 September 2023. Record date 15 September 2023. Payment date 29 September 2023.
お知らせ • Jul 04Hang Lung Group Limited to Report First Half, 2023 Results on Jul 31, 2023Hang Lung Group Limited announced that they will report first half, 2023 results on Jul 31, 2023
Upcoming Dividend • Apr 26Upcoming dividend of HK$0.65 per share at 6.3% yieldEligible shareholders must have bought the stock before 03 May 2023. Payment date: 19 May 2023. Payout ratio is a comfortable 43% and this is well supported by cash flows. Trailing yield: 6.3%. Within top quartile of German dividend payers (4.6%). Higher than average of industry peers (3.9%).
Reported Earnings • Apr 06Full year 2022 earnings released: EPS: HK$2.00 (vs HK$1.90 in FY 2021)Full year 2022 results: EPS: HK$2.00 (up from HK$1.90 in FY 2021). Revenue: HK$11.1b (up 1.7% from FY 2021). Net income: HK$2.72b (up 5.0% from FY 2021). Profit margin: 25% (in line with FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year whereas the company’s share price has fallen by 9% per year.
Buying Opportunity • Feb 16Now 20% undervaluedOver the last 90 days, the stock is up 13%. The fair value is estimated to be €2.14, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 7.7% over the last 3 years. Earnings per share has declined by 9.6%.
Reported Earnings • Feb 02Full year 2022 earnings released: EPS: HK$2.00 (vs HK$1.90 in FY 2021)Full year 2022 results: EPS: HK$2.00 (up from HK$1.90 in FY 2021). Revenue: HK$10.9b (flat on FY 2021). Net income: HK$2.72b (up 5.0% from FY 2021). Profit margin: 25% (up from 24% in FY 2021). Over the last 3 years on average, earnings per share has fallen by 10% per year and the company’s share price has also fallen by 10% per year.
お知らせ • Feb 01Hang Lung Group Limited Proposes Final Dividend for the Year Ended 31 December 2022, Payable on 19 May 2023Hang Lung Group Limited proposed Final Dividend of HKD 0.65 per share for the year ended 31 December 2022. Ex-dividend date is 03 May 2023. Record date is 05 May 2023. Payment date is 19 May 2023. Date of shareholders' approval is 28 April 2023.
Board Change • Nov 16Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 5 experienced directors. 5 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Pak Wai Liu was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Reported Earnings • Sep 18First half 2022 earnings released: EPS: HK$1.06 (vs HK$1.11 in 1H 2021)First half 2022 results: EPS: HK$1.06 (down from HK$1.11 in 1H 2021). Revenue: HK$5.72b (up 9.1% from 1H 2021). Net income: HK$1.44b (down 4.6% from 1H 2021). Profit margin: 25% (down from 29% in 1H 2021). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Sep 02Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 09 September 2022. Payment date: 29 September 2022. Payout ratio is a comfortable 46% and this is well supported by cash flows. Trailing yield: 6.4%. Within top quartile of German dividend payers (4.8%). Higher than average of industry peers (5.2%).
Recent Insider Transactions • Aug 16CEO & Executive Director recently bought €83k worth of stockOn the 10th of August, Wai Pak Lo bought around 50k shares on-market at roughly €1.67 per share. This was the largest purchase by an insider in the last 3 months. Wai Pak has been a buyer over the last 12 months, purchasing a net total of €492k worth in shares.
Reported Earnings • Jul 29First half 2022 earnings releasedFirst half 2022 results: Revenue: (down 100% from 1H 2021). Net income: (down HK$1.51b from profit in 1H 2021). Profit margin: (down from 29% in 1H 2021). The decrease in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 48% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Jul 29Hang Lung Group Limited Announces Interim Dividend for the Six Months Ended 30 June 2022, Payable on 29 September 2022Hang Lung Group Limited announced Interim Dividend for the six months ended 30 June 2022. Dividend declared is HKD 0.21 per share. Ex-dividend date is 09 September 2022. Record date is 15 September 2022. Payment date is 29 September 2022.
お知らせ • Jul 05Hang Lung Group Limited to Report First Half, 2022 Results on Jul 28, 2022Hang Lung Group Limited announced that they will report first half, 2022 results on Jul 28, 2022
お知らせ • Apr 28Hang Lung Group Limited Approves Final DividendHang Lung Group Limited approved the final dividend of 65 Hong Kong cents per share in annual general meeting held on April 27, 2022.
Board Change • Apr 27Less than half of directors are independentThere is 1 new director who has joined the board in the last 3 years. The new board member was not an independent director. The company's board is composed of: 1 new director. 7 experienced directors. 3 highly experienced directors. 4 independent directors (7 non-independent directors). Independent Non-Executive Director Pak Wai Liu was the last independent director to join the board, commencing their role in 2015. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 22Upcoming dividend of HK$0.65 per shareEligible shareholders must have bought the stock before 29 April 2022. Payment date: 19 May 2022. Payout ratio is a comfortable 45% and this is well supported by cash flows. Trailing yield: 5.2%. Within top quartile of German dividend payers (3.8%). Higher than average of industry peers (3.7%).
Reported Earnings • Jan 28Full year 2021 earnings: EPS in line with expectations, revenues disappointFull year 2021 results: EPS: HK$1.90 (up from HK$1.13 loss in FY 2020). Revenue: HK$10.9b (up 18% from FY 2020). Net income: HK$2.59b (up HK$4.13b from FY 2020). Profit margin: 24% (up from net loss in FY 2020). The move to profitability was primarily driven by lower expenses. Revenue missed analyst estimates by 11%. Over the last 3 years on average, earnings per share has fallen by 60% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 28+ 1 more updateHang Lung Group Limited Proposes Final Dividend for the Year Ended December 31, 2021, Payable on May 19, 2022Hang Lung Group Limited proposed final dividend of HKD 0.65 per share for the year ended December 31, 2021. Ex-dividend date is April 29, 2022. Record date is May 04, 2022. Payment date is May 19, 2022.
Reported Earnings • Sep 18First half 2021 earnings released: EPS HK$1.11 (vs HK$1.17 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$5.24b (up 22% from 1H 2020). Net income: HK$1.51b (up HK$3.10b from 1H 2020). Profit margin: 29% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Recent Insider Transactions • Sep 12CEO & Executive Director recently bought €307k worth of stockOn the 8th of September, Wai Pak Lo bought around 150k shares on-market at roughly €2.05 per share. This was the largest purchase by an insider in the last 3 months. This was Wai Pak's only on-market trade for the last 12 months.
Upcoming Dividend • Sep 03Upcoming dividend of HK$0.21 per shareEligible shareholders must have bought the stock before 10 September 2021. Payment date: 29 September 2021. Trailing yield: 4.4%. Within top quartile of German dividend payers (3.1%). Higher than average of industry peers (2.9%).
Recent Insider Transactions • Sep 02CFO & Executive Director recently bought €61k worth of stockOn the 26th of August, Hau Cheong Ho bought around 29k shares on-market at roughly €2.11 per share. This was the largest purchase by an insider in the last 3 months. Hau Cheong has been a buyer over the last 12 months, purchasing a net total of €107k worth in shares.
Reported Earnings • Aug 02First half 2021 earnings released: EPS HK$1.11 (vs HK$1.17 loss in 1H 2020)The company reported a strong first half result with improved earnings, revenues and profit margins. First half 2021 results: Revenue: HK$5.24b (up 22% from 1H 2020). Net income: HK$1.51b (up HK$3.10b from 1H 2020). Profit margin: 29% (up from net loss in 1H 2020). Over the last 3 years on average, earnings per share has fallen by 62% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Executive Departure • May 07Director of General Counsel has left the companyOn the 1st of May, Ka Man Yan's tenure as Director of General Counsel ended after 3.8 years in the role. We don't have any record of a personal shareholding under Ka Man's name. Ka Man is the only executive to leave the company over the last 12 months.
お知らせ • May 01Hang Lung Group Limited Declares Final Dividend for the Year 2020Hang Lung Group Limited declares a final dividend of 63 Hong Kong cents per share, at its AGM to be held on April 29, 2020.
Upcoming Dividend • Apr 27Upcoming dividend of HK$0.63 per shareEligible shareholders must have bought the stock before 04 May 2021. Payment date: 20 May 2021. Trailing yield: 4.0%. Within top quartile of German dividend payers (3.2%). Higher than average of industry peers (3.1%).
Reported Earnings • Mar 26Full year 2020 earnings released: HK$1.13 loss per share (vs HK$5.01 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: HK$9.24b (down 4.0% from FY 2019). Net loss: HK$1.54b (down 123% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 8% per year, which means it has not declined as severely as earnings.
Reported Earnings • Jan 29Full year 2020 earnings released: HK$1.13 loss per share (vs HK$5.01 profit in FY 2019)The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: HK$9.53b (down 1.0% from FY 2019). Net loss: HK$1.54b (down 123% from profit in FY 2019). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 11% per year, which means it has not declined as severely as earnings.
お知らせ • Jan 28Hang Lung Group Limited, Annual General Meeting, Apr 30, 2021Hang Lung Group Limited, Annual General Meeting, Apr 30, 2021.
Is New 90 Day High Low • Jan 27New 90-day high: €2.26The company is up 19% from its price of €1.90 on 29 October 2020. The German market is up 21% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Real Estate industry, which is up 9.0% over the same period.
お知らせ • Jan 07Hang Lung Group Limited to Report Fiscal Year 2020 Results on Jan 28, 2021Hang Lung Group Limited announced that they will report fiscal year 2020 results on Jan 28, 2021
お知らせ • Nov 21Hang Lung Group Limited Enters into the Lease Agreement as Tenant with Hang Lung as the LandlordThe Board announced that Top Glorification, an indirect wholly-owned subsidiary of the Company, entered into the Lease Agreement as tenant with Hang Lung as the landlord in respect of the Premises on 20 November 2020, for a term of three years commencing on 1 November 2020 and expiring on 31 October 2023 (both days inclusive) for the operation of its restaurant "Duddell's". Pursuant to HKFRS 16, the entering into of the Agreement will require the Group to recognise the fixed portion of the lease payment for the Premises as the right-of-use assets with a cost of approximately HKD 19.0 million at initial recognition and a corresponding lease liability which represented the present value of the future lease payments. Thus, the entering into the Lease Agreement and the transactions contemplated thereunder will be regarded as deemed acquisition of asset by the Group. REASONS FOR AND BENEFITS OF ENTERING INTO THE LEASE AGREEMENT: The Group is principally engaged in operating restaurants and providing membership services for the Group's restaurants in Hong Kong. The Premises have been leased to Top Glorification since May 2013 to operate the Group 's restaurant "Duddell's". The existing lease agreement for the Premises will expire on 31 October 2020. The Lease Agreement allows "Duddell's" to operate in the same location at Premises after the expiry of the existing lease agreement on 31 October 2020, which will facilitate the long-term success of the restaurant. Based on the above, the Directors are of the view that the terms and conditions of the Lease Agreement are fair and reasonable and in the interests of the Company and its shareholders as a whole.
Is New 90 Day High Low • Oct 31New 90-day low: €1.88The company is down 7.0% from its price of €2.02 on 31 July 2020. The German market is down 4.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Real Estate industry, which is down 2.0% over the same period.
Is New 90 Day High Low • Sep 29New 90-day low: €1.94The company is down 6.0% from its price of €2.06 on 01 July 2020. The German market is up 3.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Real Estate industry, which is up 4.0% over the same period.
